Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N07 OTHER NERVOUS SYSTEM DRUGS
N07A PARASYMPATHOMIMETICS
N07AX Other parasympathomimetics
N07AX03 Cevimeline
D00661 Cevimeline hydrochloride (USAN) <JP/US>
USP drug classification [BR:br08302]
Dental and Oral Agents
Cevimeline
D00661 Cevimeline hydrochloride (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
23 Digestive organ agents
239 Miscellaneous
2399 Others
D00661 Cevimeline hydrochloride (USAN); Cevimeline hydrochloride hydrate (JAN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01490 Muscarinic cholinergic receptor agonist
DG00993 Cevimeline
D00661 Cevimeline hydrochloride
DG01719 Parasympathomimetic agent
DG00993 Cevimeline
D00661 Cevimeline hydrochloride
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00993 Cevimeline
D00661 Cevimeline hydrochloride
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00993 Cevimeline
D00661 Cevimeline hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Acetylcholine (muscarinic)
CHRM3
D00661 Cevimeline hydrochloride (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D00661
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00661
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00661
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00661
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00661
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01490 Muscarinic cholinergic receptor agonist
DG00993 Cevimeline
DG01719 Parasympathomimetic agent
DG00993 Cevimeline
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00993 Cevimeline
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00993 Cevimeline